[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

HK1130053A1 - 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions - Google Patents

4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Info

Publication number
HK1130053A1
HK1130053A1 HK09108045.9A HK09108045A HK1130053A1 HK 1130053 A1 HK1130053 A1 HK 1130053A1 HK 09108045 A HK09108045 A HK 09108045A HK 1130053 A1 HK1130053 A1 HK 1130053A1
Authority
HK
Hong Kong
Prior art keywords
fluorophenoxy
phenylmethyl
synthesis
pharmaceutical compositions
piperidine
Prior art date
Application number
HK09108045.9A
Other languages
English (en)
Inventor
Venero Aurelio Orjales
Pestana Ramon Mosquera
Duran Ma Carmen Pumar
Avello Antonio Toledo
Mori Gonzalo Canal
Martin Maravillas Bordell
Original Assignee
Faes Farma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Faes Farma Sa filed Critical Faes Farma Sa
Publication of HK1130053A1 publication Critical patent/HK1130053A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4465—Non condensed piperidines, e.g. piperocaine only substituted in position 4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Addiction (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK09108045.9A 2006-05-12 2009-09-03 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions HK1130053A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP06380112A EP1854785A1 (fr) 2006-05-12 2006-05-12 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulphonate: l'utilisation, procédé de synthèse et compositions pharmaceutiques
US11/486,350 US20070265306A1 (en) 2006-05-12 2006-07-13 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
PCT/EP2007/053582 WO2007131846A1 (fr) 2006-05-12 2007-04-12 Méthanesulfonate de 4-[(3-fluorophénoxy)phénylméthyl]pipéridine : utilisations, procédé de synthèse et compositions pharmaceutiques

Publications (1)

Publication Number Publication Date
HK1130053A1 true HK1130053A1 (en) 2009-12-18

Family

ID=37061190

Family Applications (1)

Application Number Title Priority Date Filing Date
HK09108045.9A HK1130053A1 (en) 2006-05-12 2009-09-03 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions

Country Status (24)

Country Link
US (2) US20070265306A1 (fr)
EP (2) EP1854785A1 (fr)
JP (1) JP2009536962A (fr)
KR (1) KR20090009971A (fr)
CN (1) CN101443312B (fr)
AT (1) ATE501121T1 (fr)
AU (1) AU2007251663B2 (fr)
BR (1) BRPI0710856A2 (fr)
CA (1) CA2651933A1 (fr)
CY (1) CY1111460T1 (fr)
DE (1) DE602007013040D1 (fr)
DK (1) DK2032534T3 (fr)
ES (1) ES2362683T3 (fr)
HK (1) HK1130053A1 (fr)
HR (1) HRP20110333T1 (fr)
MX (1) MX2008014439A (fr)
MY (1) MY148406A (fr)
NO (1) NO20085052L (fr)
NZ (1) NZ572714A (fr)
PL (1) PL2032534T3 (fr)
RS (1) RS51858B (fr)
RU (1) RU2412169C2 (fr)
SI (1) SI2032534T1 (fr)
WO (1) WO2007131846A1 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1854785A1 (fr) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulphonate: l'utilisation, procédé de synthèse et compositions pharmaceutiques
EP2318362B1 (fr) 2008-07-24 2013-09-25 Theravance, Inc. Composés de 3-(phénoxyphénylméthyl)pyrrolidine
US20100267743A1 (en) * 2009-04-15 2010-10-21 Stangeland Eric L 3-(phenoxypyrrolidin-3-yl-methyl)heteroaryl, 3-(phenylpyrrolidin-3-ylmethoxy)heteroaryl, and 3-(heteroarylpyrrolidin-3-ylmethoxy)heteroaryl compounds
WO2011008666A2 (fr) * 2009-07-13 2011-01-20 Theravance, Inc. Composés 3-phénoxyméthylpyrrolidines
US8273786B2 (en) * 2009-07-21 2012-09-25 Theravance, Inc. 3-phenoxymethylpyrrolidine compounds
CN103153950B (zh) 2010-10-11 2015-11-25 施万生物制药研发Ip有限责任公司 血清素再摄取抑制剂
US8501964B2 (en) 2010-12-03 2013-08-06 Theravance, Inc. Serotonin reuptake inhibitors
US9002322B2 (en) * 2011-09-29 2015-04-07 Apple Inc. Authentication with secondary approver
CN104887675B (zh) * 2014-03-05 2018-08-07 江苏恩华药业股份有限公司 [(芳氧基)(杂芳基)]甲基哌啶衍生物在制备治疗抑郁症的药物中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1203149A (en) * 1968-06-10 1970-08-26 Ici Ltd Piperidine derivatives
US6518284B2 (en) * 1998-11-18 2003-02-11 Faes, Fabrica Espanola De Productos Quimicos Y Farmaceuticos S.A. 4-substituted piperidines
ES2157148B1 (es) * 1998-11-18 2002-03-01 Faes Fabrica Espanola De Produ Nuevas piperidinas 4-sustituidas.
CN1950348A (zh) * 2004-04-30 2007-04-18 沃尼尔·朗伯有限责任公司 治疗中枢神经系统障碍的取代的吗啉化合物
EP1854785A1 (fr) * 2006-05-12 2007-11-14 Faes Farma, S.A. 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulphonate: l'utilisation, procédé de synthèse et compositions pharmaceutiques

Also Published As

Publication number Publication date
CA2651933A1 (fr) 2007-11-22
JP2009536962A (ja) 2009-10-22
RU2412169C2 (ru) 2011-02-20
EP2032534B1 (fr) 2011-03-09
CN101443312B (zh) 2011-07-06
AU2007251663A1 (en) 2007-11-22
US20070265306A1 (en) 2007-11-15
RS51858B (en) 2012-02-29
AU2007251663B2 (en) 2012-04-05
ATE501121T1 (de) 2011-03-15
BRPI0710856A2 (pt) 2011-05-17
CY1111460T1 (el) 2015-08-05
HRP20110333T1 (hr) 2011-06-30
MY148406A (en) 2013-04-30
EP2032534A1 (fr) 2009-03-11
WO2007131846A1 (fr) 2007-11-22
EP1854785A1 (fr) 2007-11-14
ES2362683T3 (es) 2011-07-11
DE602007013040D1 (de) 2011-04-21
PL2032534T3 (pl) 2011-08-31
NO20085052L (no) 2008-12-04
DK2032534T3 (da) 2011-04-26
SI2032534T1 (sl) 2011-06-30
CN101443312A (zh) 2009-05-27
RU2008148941A (ru) 2010-06-20
MX2008014439A (es) 2009-01-21
NZ572714A (en) 2010-08-27
KR20090009971A (ko) 2009-01-23
US20100004283A1 (en) 2010-01-07

Similar Documents

Publication Publication Date Title
HK1130053A1 (en) 4-[(3-fluorophenoxy)phenylmethyl]piperidine methanesulfonate: uses, process of synthesis and pharmaceutical compositions
NO20085068L (no) Fenylamino-benzoksazolsubstituerte karboksylsyrer, fremgangsmate for deres fremstilling og anvendelse derav som medikamenter
GEP20156366B (en) Iminothiadiazine dioxide compounds as bace inhibitors, compositions, and their use
MX367154B (es) Formas solidas de acido 3-(6-(1-(2,2-difluorobenzo[d] [1,3]dioxol-5-il)ciclopropancarboxamido)-3-metilpiridin-2-il)benz oico.
EA201001585A1 (ru) Производные тиенопиридона в качестве активаторов амр-активированной протеинкиназы (амрк)
NO20090328L (no) Nye forbindelser 385
WO2005075425A3 (fr) Derives de bisaryluree
EA200970611A1 (ru) Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
MX2011011428A (es) Derivados de acido sulfamoilbenzoico como antagonistas de trpm8.
CY1115058T1 (el) Παραγωγα 1,2,3- τριαζολης για χρηση ως αναστολεις στεατοϋλο-coa δεσατουρασης
SI2150530T1 (sl) Substituirani sulfonamidni derivati
NO20091185L (no) Piperidinderivater
HK1146049A1 (en) Isoxazole derivatives as modulators of 11-beta-hydroxysteroid dehydrogenase type 1
ZA200806778B (en) N-Hydroxyacrylamide compounds
MX2007010400A (es) Nuevas sales de derivados de hexahidrofenantridina sustituida con 6-heterociclilo.
EA201071269A1 (ru) 3,4-замещенные пиперидиновые производные в качестве ингибиторов ренина
TN2009000452A1 (en) [4-(6-fluoro-7-methylamino-2,4-dioxo-1,4-dihydro-2h-quinazolin-3-yl)-phenyl] -5-chloro-thiophen-2-yl-sulfonylurea salts, in different crystalline forms, pharmaceutical compositions thereof
NZ598505A (en) 1,2-dihydro-2-oxoquinoline compounds as 5-ht4 receptor ligands
WO2008145524A3 (fr) Dérivés de pipéridine 4,4-disubstituée
WO2008036316A3 (fr) Inhibiteurs pipéridines et pyrrolidines de la bêta-secrétase utilisés dans le traitement de la maladie d'alzheimer
MX2009002906A (es) Derivados de piridina para el tratamiento de trastornos metabolicos relacionados con la resistencia a insulina o hiperglicemia.
TW200728281A (en) Novel N-sulfamoyl-piperidineamides for the prophylaxis or treatment of obesity and related conditions
EA201171229A1 (ru) Терапевтическое применение производных хиназолиндиона при сердечно-сосудистых заболеваниях
MX2010004505A (es) Piperidinas 4,4-disustituidas.
WO2007102769A3 (fr) Composés chimiques iii

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20150412